Phase II study of FOLFOX4 with "wait and go" strategy as first-line treatment for metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1215-1222

  Kochi, Mitsugu ^a   Ichikawa, Wataru ^b   Meguro, Eiji ^c   Shibata, Hiroyuki ^d   Fukui, Takuji ^e   Nagase, Michitaka ^f   Hoshino, Yutaka ^g   Takeuchi, Masahiro ^h   Fujii, Masashi ^a   Nakajima, Toshifusa ⁱ  

^a NIHON UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c Hakodate Goryokaku Hospital   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e Midori Municipal Hospital   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^h KITASATO UNIVERSITY   (Japan)

ⁱ Japan Clinical Cancer Research Organization   (Japan)

Author keywords

"Wait and go"; FOLFOX; Metastatic colorectal cancer; Neuropathy; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EVALUATION; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 82455192258     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1605-0     Document Type: Article

References (23)

1. T Andre C Boni L Mounedji-Boudiaf M Navarro J Tabernero T Hickish C Topham M Zaninelli P Clingan J Bridgewater I Tabah-Fisch A de Gramont 2004 Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2343 2351 10.1056/NEJMoa032709 15175436 10.1056/NEJMoa032709 1:CAS:528:DC%2BD2cXks1Gjt78%3D (Pubitemid 38702845)
2. T Andre C Boni M Navarro J Tabernero T Hickish C Topham A Bonetti P Clingan J Bridgewater F Rivera A de Gramont 2009 Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 3109 3116 10.1200/JCO.2008.20.6771 19451431 10.1200/JCO.2008.20.6771 1:CAS:528: DC%2BD1MXhtFWitbzF
3. C Bokemeyer I Bondarenko A Makhson JT Hartmann J Aparicio F de Braud S Donea H Ludwig G Schuch C Stroh AH Loos A Zubel P Koralewski 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663 671 10.1200/JCO.2008.20.8397 19114683 10.1200/JCO.2008.20.8397 1:CAS:528: DC%2BD1MXjsVCjsrk%3D
4. Cassidy J, Bjarnason G, Hickish T, Topham C, Provencio G, Bodoky G, Landherr L, Koralewski P, Lopez-Vivanco G, Said G (2006) Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 24(Suppl):18S (Abstr 3507)
5. A de Gramont A Figer M Seymour M Homerin A Hmissi J Cassidy C Boni H Cortes-Funes A Cervantes G Freyer D Papamichael N Le Bail C Louvet D Hendler F de Braud C Wilson F Morvan A Bonetti 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947 10944126 (Pubitemid 30644117)
6. JY Douillard S Siena J Cassidy J Tabernero R Burkes M Barugel Y Humblet G Bodoky D Cunningham J Jassem F Rivera I Kocakova P Ruff M Blasinska-Morawiec M Smakal JL Canon M Rother KS Oliner M Wolf J Gansert 2010 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 4697 4705 10.1200/JCO.2009.27.4860 20921465 10.1200/JCO.2009.27.4860 1:CAS:528:DC%2BC3cXhsF2rtLzI
7. C Eng 2009 Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer Nat Rev Clin Oncol 6 207 218 10.1038/nrclinonc.2009.16 19333227 10.1038/nrclinonc.2009.16 1:CAS:528:DC%2BD1MXktVCmtL0%3D
8. Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A (2008) Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26:1188-1189; author reply 1189-1190. doi: 10.1200/JCO.2007.15.3767
9. RM Goldberg DJ Sargent RF Morton CS Fuchs RK Ramanathan SK Williamson BP Findlay HC Pitot SR Alberts 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30 10.1200/JCO.2004.09.046 14665611 10.1200/JCO.2004.09.046 1:CAS:528: DC%2BD2cXpsVKitbY%3D (Pubitemid 41095110)
10. A Grothey 2005 Clinical management of oxaliplatin-associated neurotoxicity Clin Colorectal Cancer 5 Suppl 1 S38 S46 15871765 10.3816/CCC.2005.s.006 1:CAS:528:DC%2BD2MXltFSjs7k%3D
11. Grothey A, Nikcevich D, Sloan J, Kugler J, Silberstein P, Dentchev T, Wender D, Novotny P, Chitaley U, Alberts S, Loprinzi C (2010) Intravenous calcium and magnesium For oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7J Clin Oncol published online on December 28, 2010. doi: 10.1200/JCO.2010.1231.5911
12. HS Hochster A Grothey BH Childs 2007 Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity J Clin Oncol 25 4028 4029 10.1200/JCO.2007.13.5251 17664456 10.1200/JCO.2007.13.5251 (Pubitemid 47477294)
13. JP Kuebler HS Wieand MJ O'Connell RE Smith LH Colangelo G Yothers NJ Petrelli MP Findlay TE Seay JN Atkins JL Zapas JW Goodwin L Fehrenbacher RK Ramanathan BA Conley PJ Flynn G Soori LK Colman EA Levine KS Lanier N Wolmark 2007 Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol 25 2198 2204 10.1200/JCO.2006.08.2974 17470851 10.1200/JCO.2006.08.2974 1:CAS:528:DC%2BD2sXnsVShtL0%3D (Pubitemid 46954643)
14. SR Land JA Kopec RS Cecchini PA Ganz HS Wieand LH Colangelo K Murphy JP Kuebler TE Seay BM Needles JD Bearden III LK Colman KS Lanier ER Pajon Jr D Cella RE Smith MJ O'Connell JP Costantino N Wolmark 2007 Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07 J Clin Oncol 25 2205 2211 10.1200/JCO.2006.08.6652 17470850 10.1200/JCO.2006.08.6652 1:CAS:528:DC%2BD2sXnsVShtLk%3D (Pubitemid 46954644)
15. GD Leonard MA Wright MG Quinn S Fioravanti N Harold B Schuler RR Thomas JL Grem 2005 Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer BMC Cancer 5 116 10.1186/1471-2407-5-116 16168057 10.1186/1471-2407-5-116 (Pubitemid 41461019)
16. F Levi JL Misset S Brienza R Adam G Metzger M Itzakhi JP Caussanel F Kunstlinger S Lecouturier A Descorps-Declere, et al. 1992 A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer Cancer 69 893 900 1735081 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X 1:STN:280:DyaK387js1ehuw%3D%3D
17. FA Levi R Zidani JM Vannetzel B Perpoint C Focan R Faggiuolo P Chollet C Garufi M Itzhaki L Dogliotti, et al. 1994 Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial J Natl Cancer Inst 86 1608 1617 7932825 10.1093/jnci/86.21.1608 1:STN:280:DyaK2M%2FhvVensg%3D%3D (Pubitemid 24336347)
18. ML Rothenberg AM Oza RH Bigelow JD Berlin JL Marshall RK Ramanathan LL Hart S Gupta CA Garay BG Burger N Le Bail DG Haller 2003 Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2059 2069 10.1200/JCO.2003.11.126 12775730 10.1200/JCO.2003.11.126 1:CAS:528:DC%2BD2cXpsVGqtL4%3D (Pubitemid 46606353)
19. LB Saltz S Clarke E Diaz-Rubio W Scheithauer A Figer R Wong S Koski M Lichinitser TS Yang F Rivera F Couture F Sirzen J Cassidy 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 10.1200/JCO.2007.14.9930 18421054 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D
20. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
21. C Tournigand T Andre E Achille G Lledo M Flesh D Mery-Mignard E Quinaux C Couteau M Buyse G Ganem B Landi P Colin C Louvet A de Gramont 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229 237 10.1200/JCO.2004.05.113 14657227 10.1200/JCO.2004.05.113 1:CAS:528:DC%2BD2cXpsVKit7w%3D (Pubitemid 41095086)
22. C Tournigand A Cervantes A Figer G Lledo M Flesch M Buyse L Mineur E Carola PL Etienne F Rivera I Chirivella N Perez-Staub C Louvet T Andre I Tabah-Fisch A de Gramont 2006 OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study J Clin Oncol 24 394 400 10.1200/JCO.2005.03.0106 16421419 10.1200/JCO.2005.03.0106 1:CAS:528:DC%2BD28XhsFSku7w%3D (Pubitemid 46630458)
23. A Trotti AD Colevas A Setser E Basch 2007 Patient-reported outcomes and the evolution of adverse event reporting in oncology J Clin Oncol 25 5121 5127 10.1200/JCO.2007.12.4784 17991931 10.1200/JCO.2007.12.4784 (Pubitemid 350232293)